The Impact of Efflux Transporters in the Brain on the Development of Drugs for CNS Disorders

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Clinical Pharmacokinetics

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.2165/00003088-200241020-00001PMID 11888329
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Neotrofin is transported out of brain by a saturable mechanism: possible involvement of multidrug resistance and monocarboxylic acid transporters.

  2002cited by this paper
• Structural and functional characteristics and tissue distribution pattern of rat OCTN1, an organic cation transporter, cloned from placenta.

  2000cited by this paper
• Brain Microvascular P-Glycoprotein and a Revised Model of Multidrug Resistance in Brain

  2000cited by this paper
• Expression, transport properties, and chromosomal location of organic anion transporter subtype 3.

  2000cited by this paper
• Blood—Brain Barrier Is Involved in the Efflux Transport of a Neuroactive Steroid, Dehydroepiandrosterone Sulfate, via Organic Anion Transporting Polypeptide 2

  2000cited by this paper
• Effect of P-glycoprotein modulation with cyclosporin A on cerebrospinal fluid penetration of doxorubicin in non-human primates

  2000cited by this paper
• Molecular and Functional Characterization of Organic Cation/Carnitine Transporter Family in Mice*

  2000cited by this paper
• Enhanced cerebral uptake of receptor ligands by modulation of P‐glycoprotein function in the blood–brain barrier

  2000cited by this paper
• Functional expression of p‐glycoprotein and multidrug resistance‐associated protein (mrp1) in primary cultures of rat astrocytes

  2000cited by this paper
• Brain distribution of 6-mercaptopurine is regulated by the efflux transport system in the blood-brain barrier.

  2000cited by this paper
• Xenobiotic transport across isolated brain microvessels studied by confocal microscopy.

  2000cited by this paper
• Expression of various multidrug resistance-associated protein (MRP) homologues in brain microvessel endothelial cells.

  2000cited by this paper
• Cellular and molecular aspects of drug transport in the kidney.

  2000cited by this paper
• Multidrug resistance protein 1 protects the choroid plexus epithelium and contributes to the blood-cerebrospinal fluid barrier.

  2000cited by this paper
• The multispecific organic anion transporter (OAT) family

  2000cited by this paper
• New advances in the transport of doxorubicin through the blood-brain barrier by a peptide vector-mediated strategy.

  2000cited by this paper
• Developmental expression of P-glycoprotein (multidrug resistance gene product) in the rat brain.

  1999cited by this paper
• Monocarboxylate transporter (MCT1) abundance in brains of suckling and adult rats: a quantitative electron microscopic immunogold study.

  1999cited by this paper
• Molecular Cloning and Characterization of a New Multispecific Organic Anion Transporter from Rat Brain*

  1999cited by this paper
• Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier.

  1999cited by this paper
• What is the Blood-Brain Barrier? A Molecular Perspective

  1999cited by this paper
• Transepithelial transport of organic anions across the choroid plexus: possible involvement of organic anion transporter and multidrug resistance-associated protein.

  1999cited by this paper
• Molecular cloning and functional expression of a multispecific organic anion transporter from human kidney.

  1999cited by this paper
• Functional characteristics and tissue distribution pattern of organic cation transporter 2 (OCTN2), an organic cation/carnitine transporter.

  1999cited by this paper
• pABC11 (Also Known as MOAT-C and MRP5), a Member of the ABC Family of Proteins, Has Anion Transporter Activity but Does Not Confer Multidrug Resistance When Overexpressed in Human Embryonic Kidney 293 Cells*

  1999cited by this paper
• Physiology and pathology of the blood-brain barrier: implications for microbial pathogenesis, drug delivery and neurodegenerative disorders.

  1999cited by this paper
• Efflux transport of a new quinolone antibacterial agent, HSR-903, across the blood-brain barrier.

  1999cited by this paper
• The multidrug resistance protein family.

  1999cited by this paper
• Expression of human MRP6, a homologue of the multidrug resistance protein gene MRP1, in tissues and cancer cells.

  1999cited by this paper
• The proton-linked monocarboxylate transporter (MCT) family: structure, function and regulation.

  1999cited by this paper
• What is the blood-brain barrier? A molecular perspective. Cerebral vascular biology.

  1999cited by this paper
• P-Glycoprotein, a gatekeeper in the blood-brain barrier.

  1999cited by this paper
• Modulation of multidrug resistance protein expression in porcine brain capillary endothelial cells in vitro.

  1999cited by this paper
• Multidrug Resistance‐Related Transport Proteins in Isolated Human Brain Microvessels and in Cells Cultured from These Isolates

  1998cited by this paper
• Characterization of efflux transport of organic anions in a mouse brain capillary endothelial cell line.

  1998cited by this paper
• Molecular and Functional Identification of Sodium Ion-dependent, High Affinity Human Carnitine Transporter OCTN2*

  1998cited by this paper
• Multidrug Resistance Protein 1 Protects the Oropharyngeal Mucosal Layer and the Testicular Tubules against Drug-induced Damage

  1998cited by this paper
• Cloning and sequencing of four new mammalian monocarboxylate transporter (MCT) homologues confirms the existence of a transporter family with an ancient past.

  1998cited by this paper
• Cloning and Functional Characterization of a Potential-sensitive, Polyspecific Organic Cation Transporter (OCT3) Most Abundantly Expressed in Placenta*

  1998cited by this paper
• Identity of the Organic Cation Transporter OCT3 as the Extraneuronal Monoamine Transporter (uptake2) and Evidence for the Expression of the Transporter in the Brain*

  1998cited by this paper
• Monocarboxylate transporter expression in mouse brain.

  1998cited by this paper
• Human neurons express the polyspecific cation transporter hOCT2, which translocates monoamine neurotransmitters, amantadine, and memantine.

  1998cited by this paper
• Mrp1 Multidrug Resistance‐Associated Protein and P‐Glycoprotein Expression in Rat Brain Microvessel Endothelial Cells

  1998cited by this paper
• Molecular Characterization and Tissue Distribution of a New Organic Anion Transporter Subtype (oatp3) That Transports Thyroid Hormones and Taurocholate and Comparison with oatp2*

  1998cited by this paper
• Expression of multidrug resistance-associated protein (MRP) in brain microvessel endothelial cells.

  1998cited by this paper
• Aluminum transport out of brain extracellular fluid is proton dependent and inhibited by mersalyl acid, suggesting mediation by the monocarboxylate transporter (MCT1).

  1998cited by this paper
• Dichotomous development of the organic anion transport protein in liver and choroid plexus.

  1998cited by this paper
• Expression of the monocarboxylate transporter MCT2 by rat brain glia

  1998cited by this paper
• Multidrug resistance and its reversal.

  1998cited by this paper
• The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors.

  1998cited by this paper
• Monocarboxylate transporter expression in mouse brain.

  1998cited by this paper
• Organic cation transporters in intestine, kidney, liver, and brain.

  1998cited by this paper
• In Vivo Evidence for Carrier-Mediated Efflux Transport of 3 (cid:57) -Azido-3 (cid:57) -Deoxythymidine and 2 (cid:57) ,3 (cid:57) -Dideoxyinosine Across the Blood-Brain Barrier via a Probenecid-Sensitive Transport System 1

  1997cited by this paper
• Brain Microvascular and Astrocyte Localization of P‐Glycoprotein

  1997cited by this paper
• Quantitative evaluation of brain distribution and blood-brain barrier efflux transport of probenecid in rats by microdialysis: possible involvement of the monocarboxylic acid transport system.

  1997cited by this paper
• Increased sensitivity to anticancer drugs and decreased inflammatory response in mice lacking the multidrug resistance-associated protein

  1997cited by this paper
• Cloning of the monocarboxylate transporter isoform MCT2 from rat testis provides evidence that expression in tissues is species-specific and may involve post-transcriptional regulation.

  1997cited by this paper
• P-glycoprotein is strongly expressed in the luminal membranes of the endothelium of blood vessels in the brain.

  1997cited by this paper
• Cloning and characterization of a novel human pH‐dependent organic cation transporter, OCTN1

  1997cited by this paper
• Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines.

  1997cited by this paper
• The multidrug-resistance P-glycoprotein (Pgp, MDR1) is an early marker of blood-brain barrier development in the microvessels of the developing human brain

  1997cited by this paper
• Aluminum citrate is transported from brain into blood via the monocarboxylic acid transporter located at the blood-brain barrier.

  1997cited by this paper
• Zidovudine transport within the rabbit brain during intracerebroventricular administration and the effect of probenecid.

  1997cited by this paper
• The P-Glycoprotein Efflux Pump: How Does it Transport Drugs?

  1997cited by this paper
• Isolation of a multispecific organic anion and cardiac glycoside transporter from rat brain.

  1997cited by this paper
• Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833.

  1997cited by this paper
• In vivo evidence for carrier-mediated efflux transport of 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine across the blood-brain barrier via a probenecid-sensitive transport system.

  1997cited by this paper
• Expression of monocarboxylate transporter MCT1 by brain endothelium and glia in adult and suckling rats.

  1997cited by this paper
• Effect of the P-glycoprotein inhibitor, SDZ PSC 833, on the blood and brain pharmacokinetics of colchicine.

  1997cited by this paper
• Altered Expression and Function of P-Glycoprotein (170 Kda), Encoded by the MDR 1 Gene, in T Cell Subsets from Aging Humans

  1997cited by this paper
• Primary Structure and Functional Expression of the Apical Organic Cation Transporter from Kidney Epithelial LLC-PK1Cells*

  1997cited by this paper
• Inhibitors of multidrug resistance

  1997cited by this paper
• Lung resistance protein (LRP) expression in human normal tissues in comparison with that of MDR1 and MRP.

  1997cited by this paper
• P-Glycoprotein mediates the efflux of quinidine across the blood-brain barrier.

  1997cited by this paper
• Kinetic evidence for active efflux transport across the blood-brain barrier of quinolone antibiotics.

  1997cited by this paper
• Disruption of the murine MRP (multidrug resistance protein) gene leads to increased sensitivity to etoposide (VP-16) and increased levels of glutathione.

  1997cited by this paper
• The choroid plexus epithelium is the site of the organic anion transport protein in the brain.

  1997cited by this paper
• Cloning and functional expression of a human liver organic cation transporter.

  1997cited by this paper
• Role of P‐Glycoprotein in the Blood‐Brain Transport of Colchicine and Vinblastine

  1996cited by this paper
• P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs.

  1996cited by this paper
• Tissue distribution of the multidrug resistance protein.

  1996cited by this paper
• Dose-dependent brain penetration of SDZ PSC 833, a novel multidrug resistance-reversing cyclosporin, in rats

  1996cited by this paper
• Cellular localization of P-glycoprotein in brain versus gonadal capillaries.

  1996cited by this paper
• Structure and expression of the messenger RNA encoding the murine multidrug resistance protein, an ATP-binding cassette transporter.

  1996cited by this paper
• P-glycoprotein and multidrug resistance.

  1996cited by this paper
• Functional Expression of P‐Glycoprotein in an Immortalised Cell Line of Rat Brain Endothelial Cells, RBE4

  1996cited by this paper
• Modulation effects of cyclosporine on etoposide pharmacokinetics and CNS distribution in the rat utilizing microdialysis.

  1996cited by this paper
• Effect of para-aminohippurate on the efflux of valproic acid from the central nervous system of the rabbit.

  1996cited by this paper
• P-glycoprotein confers methotrexate resistance in 3T6 cells with deficient carrier-mediated methotrexate uptake.

  1996cited by this paper
• MDR1 P-glycoprotein is expressed by endothelial cells of newly formed capillaries in human gliomas but is not expressed in the neovasculature of other primary tumors.

  1996cited by this paper
• Substantial excretion of digoxin via the intestinal mucosa and prevention of long‐term digoxin accumulation in the brain by the mdrla P‐glycoprotein

  1996cited by this paper
• Mouse multidrug resistance 1a/3 gene is the earliest known endothelial cell differentiation marker during blood‐brain barrier development

  1995cited by this paper
• Isoform I (mdr3) is the major form of P-glycoprotein expressed in mouse brain capillaries. Evidence for cross-reactivity of antibody C219 with an unrelated protein.

  1995cited by this paper
• Zidovudine transport in the rabbit brain during intravenous and intracerebroventricular infusion.

  1995cited by this paper
• Decreased biotolerability for ivermectin and cyclosporin a in mice exposed to potent P‐glycoprotein inhibitors

  1995cited by this paper
• MDR1 Gene Expression in Brain of Patients with Medically Intractable Epilepsy

  1995cited by this paper
• P-glycoprotein of blood brain barrier: cross-reactivity of Mab C219 with a 190 kDa protein in bovine and rat isolated brain capillaries.

  1995cited by this paper
• Functional expression of the P-glycoproteinmdr in primary cultures of bovine cerebral capillary endothelial cells

  1995cited by this paper
• Comparisons of P‐glycoprotein expression in isolated rat brain microvessels and in primary cultures of endothelial cells derived from microvasculature of rat brain, epididymal fat pad and from aorta

  1995cited by this paper
• Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A.

  1995cited by this paper

• Strategies for blood-brain barrier rejuvenation and repair.

  2026cites this paper
• Exploring the genetic influences on equine analgesic efficacy through genome-wide association analysis of ranked pain responses.

  2025cites this paper
• Improved feedback loop control for ultrasound-assisted blood–brain barrier opening in non-human primates based on the discrimination between intra- and extra-cerebral cavitation

  2025cites this paper
• Imaging strategies to assess efficacy and safety of ultrasound-induced blood-brain barrier opening

  2025cites this paper
• The Bifunctional Dimer Caffeine-Indan Attenuates α-Synuclein Misfolding, Neurodegeneration and Behavioral Deficits after Chronic Stimulation of Adenosine A1 Receptors

  2024cites this paper
• Circadian Rhythms of the Blood-Brain Barrier and Drug Delivery.

  2024cites this paper
• Effects of Commonly used Surfactants, Poloxamer 188 and Tween 80, on the Drug Transport Capacity of Intestinal Glucose Transporters

  2024cites this paper
• Monitoring holograms for therapeutic ultrasound using passive cavitation beamforming

  2024cites this paper
• Focused ultrasound blood-brain barrier disruption in high-grade gliomas: Scoping review of clinical studies.

  2024cites this paper
• Recent update on pharmacokinetics and drug metabolism in CNS-based drug discovery.

  2023cites this paper
• AFETY OF CEREBROLYSIN FOR NEURORECOVERY AFTER ACUTE ISCHEMIC STROKE: A SYSTEMATIC REVIEW AND META-ANALYSIS OF TWELVE RANDOMIZED-CONTROLLED TRIALS

  2023cites this paper
• Cell type-targeting nanoparticles in treating central nervous system diseases: Challenges and hopes

  2023cites this paper
• Containers Based Drug Delivery for Neuroscience

  2022cites this paper
• Relevance of ABC Transporters in Drug Development.

  2022cites this paper
• Naturally Occurring Antioxidant Therapy in Alzheimer’s Disease

  2022cites this paper
• Evaluation of human peptide/histidine transporter 1 (hPHT1/SLC15A4) function: transport kinetics utilizing a HPHT1 shRNA stably transfected knockdown in the hCMEC/D3 blood-brain barrier cell line

  2021cites this paper
• Combination antipsychotics therapy for schizophrenia and related psychotic disorders interventions: Emergence to nanotechnology and herbal drugs

  2021cites this paper
• Current State of Targeted Radiometal-Based Constructs for the Detection and Treatment of Disease in the Brain.

  2021cites this paper
• The Blood–Brain Barrier and CNS Drug Delivery

  2021cites this paper
• Safety of Cerebrolysin for Neurorecovery after Acute Ischemic Stroke: A Systematic Review and Meta-Analysis of Twelve Randomized-Controlled Trials

  2021cites this paper
• Nanoparticle-Guided Brain Drug Delivery: Expanding the Therapeutic Approach to Neurodegenerative Diseases

  2021cites this paper
• Modified biopolymer-based systems for drug delivery to the brain

  2021cites this paper
• Correction

  2021cites this paper
• Influence of transporters in treating cancers in the CNS

  2020cites this paper
• Antifungal drugs: An updated review of central nervous system pharmacokinetics

  2020cites this paper
• Advances in blood–brain barrier modeling in microphysiological systems highlight critical differences in opioid transport due to cortisol exposure

  2020cites this paper
• Focused ultrasound for opening blood-brain barrier and drug delivery monitored with positron emission tomography.

  2020cites this paper
• Neuroimaging in Psychiatric Drug Development and Radioligand Development for New Targets

  2020cites this paper
• The Blood-Brain Barrier Interface in Diabetes Mellitus: Dysfunctions, Mechanisms, and Approaches to Treatment.

  2020cites this paper
• QUALITATIVE AND QUANTITATIVE ESTIMATION OF EUPHORBIA THYMIFOLIA LINN

  2019cites this paper
• Feedback control of microbubble cavitation for ultrasound-mediated blood–brain barrier disruption in non-human primates under magnetic resonance guidance

  2019cites this paper
• Fungal Infections of the Central Nervous System in Small Animals: Clinical Features, Diagnosis, and Management.

  2018cites this paper
• Challenges and innovations of drug delivery in older age

  2018cites this paper
• Combating the HIV reservoirs

  2018cites this paper
• The Blood-Brain Barriers

  2017cites this paper
• Managing interactions between cognitive enhancers and other psychotropics

  2017cites this paper
• P-glycoprotein (ABCB1) and Oxidative Stress: Focus on Alzheimer's Disease

  2017cites this paper
• Effect of P-glycoprotein Mediated Inhibition in Drug Bioavailability

  2017cites this paper
• Polycyclic compounds as carriers for neuroactive non- steroidal anti-inflammatory drugs

  2017cites this paper
• Discerning the Potential of Chitosan Extracted from Bio Resources as a Competent Brain Drug Carrier to Cross the Blood Brain Barrier

  2017cites this paper
• Drug delivery to melanoma brain metastases: Can current challenges lead to new opportunities?

  2017cites this paper
• Butylglyceryl-modified polysaccharide nanoparticles for drug delivery to the brain

  2016cites this paper
• Pharmacotherapy for Mood and Anxiety Disorders

  2016cites this paper
• Managing drug-resistant epilepsy: challenges and solutions

  2016cites this paper
• Challenges in the Delivery of Therapies to Melanoma Brain Metastases

  2016cites this paper
• Prodrug strategies for brain delivery

  2015cites this paper
• PET-CT imaging with [(18)F]-gefitinib to measure Abcb1a/1b (P-gp) and Abcg2 (Bcrp1) mediated drug-drug interactions at the murine blood-brain barrier.

  2015cites this paper
• The Expression and Function of ABC Transporters at the Blood-Brain Barrier

  2015cites this paper
• Control of Inflammation Using Drug Delivery Strategies in in vitro Models

  2015cites this paper
• Bypassing P-Glycoprotein Drug Efflux Mechanisms: Possible Applications in Pharmacoresistant Schizophrenia Therapy

  2015influential citation
• Public health and components of particulate matter: The changing assessment of black carbon

  2014cites this paper
• Pharmacokinetic/Pharmacodynamic (PK/PD) Analysis using Positron Emission Tomography (PET) for Preclinical Evaluation of E2110

  2014cites this paper
• BRITISH BIOMEDICAL BULLETIN

  2014cites this paper
• Challenges of Drug Delivery

  2014cites this paper
• Management and Mitigation of Human Drug-drug Interaction Risks in the Drug Discovery and Development Phases

  2014cites this paper
• Clinical Pharmacokinetics of Antibacterials in Cerebrospinal Fluid

  2013cites this paper
• Cortical organotypic slice cultures as a tool to analyze the neurovascular unit in hypoxia/ischemia and hypothermia-induced neuroprotection

  2013cites this paper
• IMAGING DRUG DELIVERY TO THE CNS USING TRANSLATIONAL POSITRON EMISSION TOMOGRAPHY STUDIES

  2013cites this paper
• Medicinal Chemistry Based Approaches and Nanotechnology‐Based Systems to Improve CNS Drug Targeting and Delivery

  2013cites this paper
• Advances in brain targeting and drug delivery of anti-HIV therapeutic agents

  2013cites this paper
• Brain meets body: the blood-brain barrier as an endocrine interface.

  2012cites this paper
• A positron emission tomography microdosing study with sertraline in healthy volunteers.

  2012cites this paper
• 6. Chemical Delivery Systems

  2012cites this paper
• Albendazole potentiates the neurotoxic effect of ivermectin in rat

  2012cites this paper
• Protection against tauopathy by the drug candidates NAP (davunetide) and D-SAL: biochemical, cellular and behavioral aspects.

  2011cites this paper
• A Review: Methods of Drug Targeting to the Brain

  2011cites this paper
• Distribution of Glycylsarcosine and Cefadroxil among Cerebrospinal Fluid, Choroid Plexus, and Brain Parenchyma after Intracerebroventricular Injection is Markedly Different between Wild-Type and Pept2 Null Mice

  2011influential citation
• In vitro primary human and animal cell-based blood-brain barrier models as a screening tool in drug discovery.

  2011cites this paper
• In vitro and In vivo Relevance of the P-glycoprotein Probe Substrates in Drug Discovery and Development: Focus on Rhodamine 123, Digoxin and Talinolol

  2011cites this paper
• Targeted Drug Delivery Across Blood-Brain-Barrier Using Cell Penetrating Peptides Tagged Nanoparticles

  2011cites this paper
• ACTIVE EFFLUX TRANSPORT AND CNS DISTRIBUTION OF THE NOVEL ANTIFOLATE PEMETREXED

  2010cites this paper
• Preservation of transendothelial glucose transporter 1 and P-glycoprotein transporters in a cortical slice culture model of the blood-brain barrier.

  2010cites this paper
• Analytical characterization and comparison of the blood-brain barrier permeability of eight opioid peptides.

  2010cites this paper
• Carbon-11 labeled tracers for in vivo imaging P-glycoprotein function: kinetics, advantages and disadvantages.

  2010cites this paper
• ABC Transporters and Drug Efflux at the Blood-Brain Barrier

  2010cites this paper
• Medulloblastoma in childhood: revisiting intrathecal therapy in infants and children

  2010cites this paper
• Inhibition of brain tumor growth by intravenous poly(β-l-malic acid) nanobioconjugate with pH-dependent drug release

  2010cites this paper
• New strategies in the management of leptomeningeal metastases.

  2010cites this paper
• Accumulation of Drugs in Tissues

  2010cites this paper
• Multifunctional Nanocarriers for diagnostics, drug delivery and targeted treatment across blood-brain barrier: perspectives on tracking and neuroimaging

  2010cites this paper
• Nano-interventions for neurodegenerative disorders.

  2010cites this paper
• Evaluation of [11C]laniquidar as a tracer of P-glycoprotein: radiosynthesis and biodistribution in rats.

  2009cites this paper
• Delivery of peptide and protein drugs over the blood-brain barrier.

  2009cites this paper
• Prodrugs of Thyrotropin-Releasing Hormone and Related Peptides as Central Nervous System Agents

  2009cites this paper
• Active transport and CNS delivery of novel tyrosine kinase inhibitors.

  2009cites this paper
• Pharmacokinetics and drug metabolism in the elderly

  2009cites this paper
• The mechanisms of medically refractory temporal lobe epilepsy.

  2009cites this paper
• Characteristics of compounds that cross the blood-brain barrier

  2009cites this paper
• in the Brain : Studies of Healthy Humans C-Verapamil 11 Imaging of Cyclosporine Inhibition of P-Glycoprotein Activity Using

  2009cites this paper
• Imaging of Cyclosporine Inhibition of P-Glycoprotein Activity Using 11C-Verapamil in the Brain: Studies of Healthy Humans

  2009cites this paper
• ACTIVE TRANSPORT AND CNS DELIVERY OF NOVEL TYROSINE

  2009cites this paper
• ABCB1:theroleinParkinson's diseaseandpharmacokineticsof antiparkinsoniandrugs

  2009cites this paper
• Cytokines and the Blood–Brain Barrier

  2009cites this paper
• Isolation of Peptide Transport System-6 from Brain Endothelial Cells: Therapeutic Effects with Antisense Inhibition in Alzheimer and Stroke Models

  2009cites this paper
• ABCB1: the role in Parkinson's disease and pharmacokinetics of antiparkinsonian drugs

  2009cites this paper
• Permeability of the Blood-Brain Barrier to a Rhenacarborane

  2009cites this paper
• Design and evaluation of novel PET and SPECT tracers for imaging the monoamine system and the P-gp transporter

  2009cites this paper
• Induction of nuclear receptors and drug resistance in the brain microvascular endothelial cells treated with antiepileptic drugs.

  2008cites this paper
• The blood-brain barrier: connecting the gut and the brain.

  2008cites this paper
• Role of multidrug resistance associated proteins in drug development.

  2008cites this paper